期刊
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
卷 15, 期 7, 页码 1606-1612出版社
WILEY
DOI: 10.1111/cts.13256
关键词
-
资金
- German Research foundation [SFB-TRC 128 A08]
The impact of distinct disease-modifying therapies on the efficacy of SARS-CoV-2 vaccination in patients with multiple sclerosis is still unclear. This study investigated the immune responses in patients receiving interferon beta, natalizumab, and ocrelizumab before and after vaccination. The results showed that different therapies had different effects on humoral and cellular immune responses.
The impact of distinct disease-modifying therapies (DMTs) on severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccination efficacy in patients with multiple sclerosis (MS) is still enigmatic. In this prospective comparative study, we investigated humoral and cellular immune-responses in patients with MS receiving interferon beta, natalizumab, and ocrelizumab pre-vaccination and 6 weeks post second SARS-CoV-2 vaccination. Healthy individuals and interferon beta-treated patients generated robust humoral and cellular immune-responses. Although humoral immune responses were diminished in ocrelizumab-treated patients, cellular immune-responses were reduced in natalizumab-treated patients. Thus, both humoral and cellular immune responses should be closely monitored in patients on DMTs. Whereas patients with a poor cellular immune-response may benefit from additional vaccination cycles, patients with a diminished humoral immune-response may benefit from a treatment with SARS-CoV-2 antibodies in case of an infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据